Oxidative stress has become an exciting area of schizophrenia research, and provides ample opportunities and hope for a better understanding of its pathophysiology, which may lead to novel treatment strategies. This review describes how recent methodological advances have allowed the study of oxidative stress to tackle fundamental questions and have provided several conceptual breakthroughs to the field.
INTRODUCTION
Recent studies, in particular studies in human genetics, have indicated that multiple combinations of genetic and environmental factors underlie the cause of schizophrenia [1 && ,2]. Although it is very important to explore the comprehensive landscape of genetic architecture of the disease, investigators and clinicians have also acknowledged the importance of understanding the pathophysiological pathways that occur more commonly under the diagnostic label. As a result of the current diagnostic criteria, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM), stemming more from reliability of clinical phenotypes rather than causative validity, these pathways may not be purely disease or label specific (i.e., they may underlie both schizophrenia and bipolar disorder). Nonetheless, understanding of common pathophysiological pathways will prove to be very important in identifying the biomarkers and drug discovery efforts.
OXIDATIVE STRESS: TIMELY AND IMPORTANT TOPIC IN SCHIZOPHRENIA RESEARCH AS OF 2014
Although first postulated in the 1930s by Hoskins [3] , the significance of oxidative stress in the pathophysiology of schizophrenia has been underestimated. Oxidative stress is biologically important, but the involvement of this cascade occurs in multiple pathological conditions, including cancer, cardiovascular disease, and neurodegenerative disorders [4] [5] [6] . This nonspecific nature of oxidative stress played a role in deterring psychiatric researchers from the field. Additionally, shortage of techniques for monitoring oxidative stress inside the brain was also a concern. However, at least four conceptual and technical advances in the last decade have changed the situation.
First, important studies that reported 'specific' involvement of oxidative stress on the key biological mechanisms that may underlie the endophenotypes relevant to schizophrenia, such as role for nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in interneuron deficits, have generated new opportunities for research (described below in detail) [7] .
Second, recent progress in cell biology has allowed us to access patient-derived cells with the potential to reproduce traits of brain cells, such as neurons, in vitro. The generation of induced pluripotent stem (iPS) cells is a hot topic, given their potential to differentiate into neurons and glia [8 && ]. Furthermore, the use of cells from olfactory epithelium is also considered as an alternative approach [9,10]. Olfactory cells are advantageous to iPS cells in that they possess neural traits, but require no reprogramming and are higher throughput [11 & ]. Third, an advance in brain imaging techniques, in particular the capacity to measure the levels of glutathione (GSH), a major component of antioxidant defenses, by magnetic resonance spectroscopy (MRS) has provided us with tools for in-vivo studies [12] .
Finally, although many studies of schizophrenia patients have been challenged regarding the effect of long-term medication and other confounding factors, recent reports have provided us with the evidence of oxidative stress in recent-onset cases with minimal or no medication confounding [13 && ]. If oxidative stress is prominent in the early stage of the disease, it is very reasonable that people expect such biological change to be a target of early detection and early intervention, which always confirm better treatment outcome in any disease in medicine [14] . Taken together, oxidative stress has become an exciting area of research in schizophrenia.
WHAT IS OXIDATIVE STRESS?
Oxidative stress results from an imbalance between an overproduction of reactive oxygen species (ROS) and a deficiency of enzymatic or nonenzymatic antioxidants ( Fig. 1 ). When this homeostasis is lost, oxidative stress damages the cell structures.
Major targets of oxidative stress are proteins, lipids, and DNA [15] .
Physiological sources of ROS include oxidative phosphorylation, crucial for cellular energy generation is the predominant source, as well as NADPH oxidase. NADPH oxidase oxidizes NADPH, donating the electrons to an oxygen molecule (O 2 ) to produce superoxide (O 2 À ). Cellular antioxidant defenses include enzymatic components, such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), as well as nonenzymatic components (GSH, uric acid, vitamin C, and albumin). SOD is responsible for converting the radical form of oxygen (O 2 À ) into hydrogen peroxide (H 2 O 2 ), which can be converted to oxygen and water by CAT or GSH-Px before it converts to harmful radicals. GSH is a tripeptide that is reduced to glutathione disulfide (GSSG) by GSH-Px to convert H 2 O 2 to water.
BIOCHEMICAL EVIDENCE IN HUMAN BIOSPECIMENS
The goal of this short review is to provide current opinions on exciting frontline research. Therefore,
KEY POINTS
Recent meta-analyses and replication studies with human biospecimens have further suggested the presence and role of oxidative stress in schizophrenia.
New techniques, such as magnetic resonance spectroscopy and stem cells obtained from living patients, have allowed more thorough studies.
Genetic mouse models relevant to schizophrenia show the signs of excess oxidative stress.
We may develop novel strategies for the treatment of schizophrenia by targeting oxidative stress in its pathophysiology. we acknowledge that our coverage of the past literature is not exhaustive and only representative articles required for the present discussion are included. Human biospecimens that have been used for the study of oxidative stress include postmortem tissues as well as biopsied samples, such as blood (e.g., red blood cells, plasma, serum, lymphocytes, and lymphoblasts), fibroblasts, and cerebrospinal fluid (CSF). In addition, recent reports have utilized cutting-edge resources, such as iPS cells and olfactory cells [16 && ,17 && ]. In summary, evidence from the biochemical studies of protein contents and activity in human biospecimens has suggested that oxidative stress may exist in the pathophysiology of schizophrenia. However, as discussed below, there exist substantial discrepancies among the results.
Mitochondria
Postmortem brain analysis has suggestively shown the trace of excess oxidative stress [18, 19] . Though the study of postmortem brain is important, this has faced difficulty because of the employment of indirect measurements of oxidative stress. Furthermore, confounding factors, such as variability in the postmortem interval, are inevitable.
Schizophrenia is a condition with onset in young adulthood. Many investigators have questioned whether autopsied brain from aged patients may truly reflect the active pathophysiology. Therefore, there is great potential in the study of biopsied cells and tissues from living patients. The levels of SOD were reduced in red blood cells from individuals with first-episode psychosis as well as those from stably medicated outpatients [13 && ,20] . Consistent observation was also reported in CSF from recent-onset schizophrenia patients [21] . However, studies have shown an increase in the levels of SOD in plasma from schizophrenia patients [22] . The levels of GSH-Px were decreased in red blood cells from schizophrenia patients in acute relapse phases and from chronic inpatients [23] . Discrepancies in this result, though present, were found to be insignificant [13 && ]. Likewise, some, but not all studies, have reported a reduction of CAT in red blood cells [13 && ,24]. As described above, researchers have recently welcomed the technical advances that enable us to study cells with neural traits obtained from living patients [10,17 && ,25]. For example, the importance of stress-associated pathways has been underscored in a study with olfactory cells: of special interest were antioxidant enzyme pathways, which include proteins such as microsomal glutathione-S-transferase 1 (MGST1) [17 && ]. As far as we are aware, only a few studies utilized iPS cells in schizophrenia research. Nonetheless, two exploratory studies have already suggested the involvement of oxidative stress: one case report indicated an increase in ROS in schizophrenia [26] and another group showed that schizophrenia-derived iPS cells had difficulty in differentiating into neurons and exhibited substantial mitochondrial deficits [16 && ]. Provided that these results are supportive to the notion that oxidative stress may underlie the pathophysiology of schizophrenia, it is important to account for contradictory results in these studies. We regard that there are at least three possible reasons: first, schizophrenia is highly heterogeneous under the same clinical diagnosis. Second, redox dysfunction may be, at least in part, state dependent. Third, tissue-specific change may underlie the pathophysiology. Meta-analyses that consider these points will be useful to the field.
MAGNETIC RESONANCE SPECTROSCOPY
As described above, the most current biochemical studies utilize peripheral tissues, such as blood materials. A major breakthrough in the last decade is the use of MRS in measuring the brain levels of GSH in living individuals directly [27,28 && ]. A pioneering study in schizophrenia research was made with 1 H-MRS at 1.5 Tesla and reported a 52% reduction of GSH in the medial prefrontal cortex of drug-free patients with schizophrenia [29] . Subsequent studies, however, found difficulties in replication. The second report on brain GSH in medicated patients with schizophrenia at 4 Tesla did not report a difference in the level of GSH in the anterior cingulate [30] . The third study also failed to observe the change in prefrontal cortex using a 3 Tesla machine, but noted a negative correlation of GSH with negative symptoms [31] . The fourth group studying individuals with first-episode psychosis reported an increase in GSH in the medial temporal lobe also at 3 Tesla [32] .
Although the direct measurement of GSH in the brain of living individuals is tempting, the results are thus far inconsistent in the studies of schizophrenia. This discrepancy might be explained in part because different sequences are used for measurement and analyses in each study. The first study had been reported even before the introduction of the editing sequence [33] . In addition, although acceptable as brain imaging study, each study had a rather small sample size and observed slightly different brain regions. More fundamentally, MRS cannot distinguish intracellular from extracellular GSH: this distinction is biologically crucial, given the large difference in GSH concentrations. Thus, careful discussion on how to analyze the data of brain GSH measured by MRS is required for valid interpretation. A meta-analysis will be valuable once more studies with MRS are published.
WHAT DOES OXIDATIVE STRESS ELICIT IN THE CONTEXT OF SCHIZOPHRENIA PATHOPHYSIOLOGY?
Multiple groups have identified the neuropathological defects associated with interneurons, in particular parvalbumin-positive interneurons, in the brains of schizophrenia patients [34 & ,35,36] . Proper function of interneurons is required for the maintenance of gamma oscillations, which are responsible for cognition and are altered in schizophrenia patients [37, 38] . Recent studies in preclinical models have shown that oxidative stress preferentially affects the interneurons [7,39 & ,40,41 && ]. The effectiveness of antioxidants in rescuing parvalbumin interneurons gives credence to antioxidant therapies [41 && ]. Furthermore, the lipid-rich white matter is sensitive to oxidative stress [42] . Thus, oxidative stress may underlie myelin-associated deficits in schizophrenia [43, 44] . Oxidative stress can affect cellular signaling cascades, which may underlie the disease pathophysiology [45, 46] .
INSIGHT FROM ANIMAL MODELS
In the present chapter, we have introduced a brief summary of human studies on schizophrenia and oxidative stress. When attempting to elucidate the pathophysiology of a human disease or condition, the study of humans is essential. Nonetheless, animal models are useful in linking the pathophysiology to the pathological trajectory during neurodevelopment, and in clarifying the molecular changes in the context of neural circuitry disturbance and behavioral changes.
In a strict sense, there is no animal model for schizophrenia. However, for the present discussion, we will consider animals that show behavioral changes relevant to some endophenotypes of schizophrenia with some level of genetic evidence. Under this less stringent criterion, there exist at least three animal models that show signs of excess oxidative stress.
The first model focuses on glutamate-cysteine ligase (GCL): this is the rate-limiting enzyme in GSH production, which is composed of modifier (GCLM) and catalytic (GCLC) subunits. A trinucleotiderepeat polymorphism in the GCLC gene is reportedly associated with schizophrenia [47] . Gclm knockout mice showed a robust reduction in the level of GSH [48] . Of interest, this mouse model displayed reduced parvalbumin immunoreactivity in the CA3 and dentate gyrus, as well as predicted deficits in gamma oscillations [49] . The animals also showed deficits in prepulse inhibition and hyperlocomotion selective to environmental novelty and stress, and in response to acute amphetamine injection [50, 51] . Oxidative stress is prominent in adolescence, but the behavioral phenotypes relevant to schizophrenia become more prominent after puberty, suggesting an idea that oxidative stress may be involved in the early stage of the pathological trajectory [49, 52] . Finally, some of these abnormalities were normalized by the administration of the GSH precursor N-acetylcysteine (NAC) [52] .
DISC1 is a representative gene in which a rare variant provides strong biological influence on mental disease, such as depression and schizophrenia [53] . Transgenic mice expressing a putative dominant-negative mutant displayed a reduction in the levels of parvalbumin immunoreactivity, indicating interneuron deficits [54] . Consequently, several behavioral deficits have also reported [39 & ,54] . Given that interneuron deficits occur as downstream of oxidative stress, our group studied whether excess of oxidative stress may exist and observed the sign in the frontal cortex, in particular orbitofrontal cortex [39 & ]. Of special interest, these mice showed an augmentation of the nuclear glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cascade, which is reportedly elicited by oxidative stress [39 & ,55]. The nuclear GAPDH pathway is important in gene transcriptional and epigenetic controls upon stressors [56] , thus the augmentation of this cascade triggered by oxidative stress may underlie stress-mediated epigenetic contribution to the disease pathophysiology.
The third mouse model is deficient in excitatory amino acid transporter 3 (EAAT3/EAAC1) encoded by the gene Eaac1/Slc1a1, which reduces GSH production by limiting neuronal glutamate uptake [57] . Recent genetic studies have provided some evidence of Eaac1 association with schizophrenia [58, 59] .
TREATMENT PERSPECTIVES
In an animal model (Gclm knockout mice) that is relevant to study the biology of schizophrenia, oxidative stress occurs in early phase of the pathological trajectory and administration of NAC ameliorated the abnormal behaviors [41 && ]. Although NAC is not a compound purely specific to oxidative stress, the preclinical study provided us with a hope to use NAC and related compounds in the treatment of schizophrenia, in particular the earlier phase of schizophrenia [49] . In another model (Disc1 dominant-negative model), the nuclear GAPDH stress cascade was augmented [39 & ]. Because a set of selective compounds that block this cascade is available in humans [60] , they may be tried for possible treatment of schizophrenia.
CONCLUSION
In this short review, we have described how the story of oxidative stress in schizophrenia has been rediscovered in the last decade, according to the recent methodological advances in science. It is possible to intervene in this biological process in many ways, providing us with the hope of developing novel treatment strategies to this devastating mental condition.
